SOBI — Swedish Orphan Biovitrum AB (publ) Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedLarge CapHigh Flyer

Market Cap
SEK136.81bn
Enterprise Value
SEK147.27bn
Revenue
SEK28.24bn

Annual income statement for Swedish Orphan Biovitrum AB (publ), fiscal year end - December 31st, SEK millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	PRESS
Standards:	IFRS	IFRS	IFRS	IFRS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	15,529	18,790	22,123	26,027	28,238
Cost of Revenue
Gross Profit	12,045	14,377	17,171	20,310	22,271
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	11,796	14,977	18,057	20,402	27,371
Operating Profit	3,733	3,813	4,066	5,625	867
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	3,295	3,321	2,954	4,407	34
Provision for Income Taxes
Net Income After Taxes	2,679	2,638	2,408	3,879	476
Minority Interest
Net Income Before Extraordinary Items
Net Income	2,679	2,638	2,408	3,885	478
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	2,679	2,638	2,409	3,885	478
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	8.79	10.2	8.63	11.7	14.7
Dividends per Share